Medical Condition

hematopoietic and lymphatic system neoplasm

Total Trials

10

Recruiting Now

10

Trial Phases

Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for hematopoietic and lymphatic system neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematopoietic and lymphatic system neoplasm Clinical Trials

How many clinical trials are currently recruiting for hematopoietic and lymphatic system neoplasm?

ClinicalMetric currently tracks 10 actively recruiting clinical trials for hematopoietic and lymphatic system neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hematopoietic and lymphatic system neoplasm?

hematopoietic and lymphatic system neoplasm research spans Phase 1 (2 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hematopoietic and lymphatic system neoplasm clinical trial?

Eligibility criteria for hematopoietic and lymphatic system neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Mayo Clinic 4 trials

Children's Oncology Group 1 trial

University of Michigan Rogel Cancer Center 1 trial

Roswell Park Cancer Institute 1 trial

Yuanquan Yang 1 trial

Recruiting Clinical Trials

NCT07477886

Recruiting

Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Enrollment

60 pts

Location

United States, Canad...

Sponsor

Children's Oncology Group

View Trial →

NCT07365007

Recruiting

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment

University of Michigan Rogel C...

View Trial →

NCT06798701

Recruiting

Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation

Roswell Park Cancer Institute

View Trial →

NCT06712810 Phase 1

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

City of Hope Medical Center

View Trial →

NCT02958462

Recruiting

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

University of Washington

View Trial →

Related Conditions

malignant solid neoplasm (5) chemotherapy induced peripheral neuropathy (1) histiocytic sarcoma (1) malignant histiocytosis (1) peripheral t cell lymphoma not otherwise specified (1) primary cutaneous t cell non hodgkin lymphoma (1) recurrent chronic lymphocytic leukemia (1) recurrent chronic myelomonocytic leukemia (1) recurrent follicular lymphoma (1) recurrent langerhans cell histiocytosis (1) recurrent lymphoplasmacytic lymphoma (1) recurrent myelodysplastic syndrome (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology